Canbaz Kabay Sibel, Kabay Sahin, Mestan Emine, Cetiner Mustafa, Ayas Selahattin, Sevim Mehmet, Ozden Hilmi, Karaman Handan Ozisik
Department of Neurology, Dumlupinar University Faculty of Medicine, Kutahya, Turkey.
Department of Urology, Dumlupinar University Faculty of Medicine, Kutahya, Turkey.
Neurourol Urodyn. 2017 Jan;36(1):104-110. doi: 10.1002/nau.22868. Epub 2015 Sep 9.
The aim of this study is to determine the sustained therapeutic efficacy and treatment intervals for PTNS in NOAB with MS, offering periodic additional treatments during 1 year in patients who completed an initial course of 12 consecutive weekly sessions.
A total of 34 patients enrolled to the PTNS treatment and 21 patients completed the 1 year PTNS treatment with a tapering protocol of 6, 9, and 12 months of therapy, respectively. After 12 weeks of therapy, PTNS was applied at 14 day intervals for 3 months, 21 day intervals for 3 months, and 28 day intervals for 3 months. The patients completed a 3-day voiding diary at 3rd, 6th, 9th, and 12th month. The patients requested to complete validated questionnaires (ICIQ-SF, OAB-V8, OAB-q SF) were carried out within 3-month intervals thereafter during their enrolment in the study.
A total of 21 patients were enrolled in the study. Of these 5 (23.8%) were men and 16 (76.2%) women. The improvements for all voiding diary parameters were significant in the 6th, 9th, and 12th months when compared with baseline. Mean values between baseline and 12 month parameters suggested that daytime frequency decreased by 5.4 voids daily, urge incontinence decreased by 3.4 episodes daily, urgency episodes decreased by 7.4 episodes daily, nocturia decreased by 2.6 voids, and voided volume improved by a mean of 72.1 cc.
These results have demonstrated NOAB symptom improvement in MS patients can be achieved with 12 weekly PTNS treatments which show excellent durability over 12 months. Neurourol. Urodynam. 36:104-110, 2017. © 2015 Wiley Periodicals, Inc.
本研究旨在确定经皮胫神经刺激(PTNS)治疗绝经后非梗阻性尿潴留(NOAB)合并多发性硬化(MS)的持续治疗效果及治疗间隔时间,对完成连续12周初始疗程的患者在1年内定期进行额外治疗。
共有34例患者接受PTNS治疗,21例患者分别按照6个月、9个月和12个月的递减方案完成了1年的PTNS治疗。治疗12周后,PTNS分别以14天的间隔应用3个月、21天的间隔应用3个月、28天的间隔应用3个月。患者在第3、6、9和12个月完成一份为期3天的排尿日记。此后,在患者参与研究期间,每隔3个月要求他们完成经过验证的问卷(ICIQ-SF、OAB-V8、OAB-q SF)。
共有21例患者参与本研究。其中,5例(23.8%)为男性,16例(76.2%)为女性。与基线相比,所有排尿日记参数在第6、9和12个月均有显著改善。基线和12个月参数之间的平均值表明,白天排尿频率每天减少5.4次,急迫性尿失禁每天减少3.4次,尿急发作每天减少7.4次,夜尿每天减少2.6次,排尿量平均增加72.1毫升。
这些结果表明,每周进行12次PTNS治疗可改善MS患者的NOAB症状,且在12个月内显示出优异的持久性。《神经泌尿学与尿动力学》,2017年,第36卷,第104 - 110页。© 2015威利期刊公司。